Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A in Bruxism
NCT03827122Phase 2Unknown
- Sponsor
- Riyadh Elm University
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in bruxism, sponsored by Riyadh Elm University. Primary endpoint: Pain reduction after botox injection subjective at 48 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
bruxism
Beyond the preview
Go deeper on NCT03827122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827122.